Restructuring and Other Charges |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Restructuring and Related Activities [Abstract] | |
| Restructuring and Other Charges | (6) Restructuring and Other Charges In February 2024, the Company and its board of directors decided to discontinue the Synpheny-3 trial and announced a corporate restructuring that included a reduction in its workforce, leaving one remaining full-time employee. Following the discontinuation of Synpheny-3, Synlogic’s corporate strategy shifted to pursuing strategic initiatives to enhance stockholder value, including a potential merger or sale of the company. Synlogic initiated a strategic review process and engaged in a range of interactions with potential transaction counterparties, which ultimately resulted in the execution of the Merger Agreement (see Note 1, Organization in this Quarterly Report on Form 10-Q). We recorded restructuring and other charges of $0.2 million for the three months ended June 30, 2026, compared to a gain on restructuring of $0.01 million for the corresponding period in 2025. We recorded restructuring and other charges of $0.4 million for the six months ended June 30, 2026, compared to $0.03 million for the corresponding period in 2025. As of June 30, 2026, approximately $0.9 million of the total restructuring charges remain unpaid and were included in accrued restructuring charges. These charges primarily consist of personnel costs related to severance expense and retention bonuses. |